{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:21:12Z","timestamp":1784031672356,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-EQPX-03"],"award-info":[{"award-number":["ANR-10-EQPX-03"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Site de recherche int\u00e9gr\u00e9 contre le cancer"},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le Ile-de-France","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We set up a prospective longitudinal biobanking study answering scientific questions within a regulatory framework and patient-centered approach. We aim in this paper to present the opportunities of such a study, as well as the challenges and the limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>SCANDARE (NCT03017573) is an institutional first monocentric then multicentric biobanking study. The study enrolled adult patients with newly diagnosed head and neck squamous cell carcinoma, triple negative breast cancer, ovarian and cervical cancer. All patients signed a consent form before any procedure. Tumor tissue and blood samples are collected at several time points during patient's journey, including at diagnosis, post-neoadjuvant chemotherapy in case of neoadjuvant treatment, at surgery, at recurrence and at disease progression following treatment initiated at recurrence. Clinical data are entered into an eCRF, whereas generated data are centralized in a secure database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SCANDARE started in 2017 at Institut Curie and has included 676 patients at date. SCANDARE successfully addressed challenges related to patient consent, regulatory compliance, and logistical integration of sample collection into routine clinical practice. The study facilitated the longitudinal collection and preservation of tumor and blood samples, enabling comprehensive analyses from histopathology to genomics and proteomics needed for the 35 ongoing projects run by academic research groups and industry. The implementation of optimized sampling and data workflows enabled high-quality data. Several other cohorts are planned to open soon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SCANDARE is an institutional, prospective and dynamic biobanking study that successfully enabled the implementation of 35 research projects with clinical and omics data centralized in a secure database available for all collaborators on demand. Looking ahead, SCANDARE aims to expand its scope by including additional cancer types and patient cohorts, further enhancing the potential for translational research and personalized medicine in oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15680-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:13:41Z","timestamp":1770254021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SCANDARE: an institutional dynamic prospective interventional biobanking study"],"prefix":"10.1186","volume":"26","author":[{"given":"Constance","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onard","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Choussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lecuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Plissonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Dubray-Vautrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Borcoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Sablin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Cabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Pasquesoone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Gorret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Dias","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odette","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Delattre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bi\u00e8che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Servant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain-David","family":"Seban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Morillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Th\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Proudhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Vallot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Mechta-Grigoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Flavius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Dupain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Gentric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"15680_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28:658\u201365.","journal-title":"Nat Med"},{"key":"15680_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167\u201377.","journal-title":"N Engl J Med"},{"key":"15680_CR3","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526\u201335.","journal-title":"Ann Oncol"},{"key":"15680_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"15680_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"15680_CR6","first-page":"433","volume":"74","author":"V Subbiah","year":"2024","unstructured":"Subbiah V, Gouda MA, Ryll B, et al. The evolving landscape of tissue-agnostic therapies in precision oncology. CA Cancer J Clin. 2024;74:433\u201352.","journal-title":"CA Cancer J Clin"},{"key":"15680_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/1878-0261.12450","volume":"13","author":"U Ringborg","year":"2019","unstructured":"Ringborg U. Translational cancer research \u2013 a coherent cancer research continuum. Mol Oncol. 2019;13:517\u201320.","journal-title":"Mol Oncol"},{"key":"15680_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","volume":"18","author":"F Di Nicolantonio","year":"2021","unstructured":"Di Nicolantonio F, Vitiello PP, Marsoni S, et al. Precision oncology in metastatic colorectal cancer \u2014 from biology to medicine. Nat Rev Clin Oncol. 2021;18:506\u201325.","journal-title":"Nat Rev Clin Oncol"},{"key":"15680_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/cancers12040776","volume":"12","author":"K Lommen","year":"2020","unstructured":"Lommen K, Odeh S, De Theije CC, et al. Biobanking in molecular biomarker research for the early detection of cancer. Cancers. 2020;12:776.","journal-title":"Cancers"},{"key":"15680_CR10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/bjc.2015.401","volume":"113","author":"A Amatu","year":"2015","unstructured":"Amatu A, Somaschini A, Cerea G, et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br J Cancer. 2015;113:1730\u20134.","journal-title":"Br J Cancer"},{"key":"15680_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","volume":"381","author":"The All of Us Research Program Investigators","year":"2019","unstructured":"The All of Us Research Program Investigators. The \u201cAll of Us\u201d Research Program. N Engl J Med. 2019;381:668\u201376.","journal-title":"N Engl J Med"},{"key":"15680_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/djad151","volume":"115","author":"A Annapragada","year":"2023","unstructured":"Annapragada A, Sikora AG, Marathe H, et al. The cancer moonshot immuno-oncology translational network at 5: accelerating cancer immunotherapies. J Natl Cancer Inst. 2023;115:1262\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"15680_CR13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.21037\/tlcr-20-137","volume":"9","author":"S Wessels","year":"2020","unstructured":"Wessels S, Muley T, Christopoulos P, et al. Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. Transl Lung Cancer Res. 2020;9:1000\u201314.","journal-title":"Transl Lung Cancer Res"},{"key":"15680_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/jpm13020360","volume":"13","author":"M Abdollahyan","year":"2023","unstructured":"Abdollahyan M, Gadaleta E, Asif M, et al. Dynamic biobanking for advancing breast cancer research. J Pers Med. 2023;13:360.","journal-title":"J Pers Med"},{"key":"15680_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/030089160809400205","volume":"94","author":"PH Riegman","year":"2008","unstructured":"Riegman PH, Bosch AL, the OECI TuBaFrost Consortium*, et al. OECI TuBaFrost Tumor Biobanking. Tumori J. 2008;94:160\u20133.","journal-title":"Tumori J"},{"key":"15680_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00404-019-05395-3","volume":"301","author":"A De Gregorio","year":"2020","unstructured":"De Gregorio A, Nagel G, M\u00f6ller P, et al. Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project. Arch Gynecol Obstet. 2020;301:273\u201381.","journal-title":"Arch Gynecol Obstet"},{"key":"15680_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/s12885-015-1801-0","volume":"15","author":"C Ngo","year":"2015","unstructured":"RAIDs consortium, Ngo C, Samuels S, et al. From prospective biobanking to precision medicine: BIO-RAIDs \u2013 an EU study protocol in cervical cancer. BMC Cancer. 2015;15:842.","journal-title":"BMC Cancer"},{"key":"15680_CR18","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109\u201321.","journal-title":"N Engl J Med"},{"key":"15680_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","volume":"7","author":"AA Chaudhuri","year":"2017","unstructured":"Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394\u2013403.","journal-title":"Cancer Discov"},{"key":"15680_CR20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41467-024-45595-3","volume":"15","author":"M Licaj","year":"2024","unstructured":"Licaj M, Mhaidly R, Kieffer Y, et al. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway. Nat Commun. 2024;15:1312.","journal-title":"Nat Commun"},{"key":"15680_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jclinepi.2010.07.008","volume":"64","author":"N Balogun","year":"2011","unstructured":"Balogun N, Gentry-Maharaj A, Wozniak EL, et al. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol. 2011;64:525\u201330.","journal-title":"J Clin Epidemiol"},{"key":"15680_CR22","doi-asserted-by":"publisher","first-page":"S560","DOI":"10.1016\/j.annonc.2023.09.2010","volume":"34","author":"G Marret","year":"2023","unstructured":"Marret G, Lamy C, Vacher S, et al. 864P serial cell-free tumor DNA in prognosing survival in patients with head and neck squamous cell carcinoma treated with upfront surgery. Ann Oncol. 2023;34:S560.","journal-title":"Ann Oncol"},{"key":"15680_CR23","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1538-7445.AM2024-1620","volume":"84","author":"G Marret","year":"2024","unstructured":"Marret G, Vacher S, Lamy C, et al. Abstract 1620: multiregion spatial sequencing of early-stage head and neck squamous cell carcinoma revealed theranostic intratumor heterogeneity. Cancer Res. 2024;84:1620\u20131620.","journal-title":"Cancer Res"},{"key":"15680_CR24","doi-asserted-by":"publisher","first-page":"zcaf036","DOI":"10.1093\/narcan\/zcaf036","volume":"7","author":"N Torossian","year":"2025","unstructured":"Torossian N, Gabriel M, Papoutsoglou P, et al. Reference-free RNA profiling predicts triple negative breast cancer chemoresistance to neoadjuvant treatment. NAR Cancer. 2025;7:zcaf036.","journal-title":"NAR Cancer"},{"key":"15680_CR25","doi-asserted-by":"crossref","unstructured":"Hofer I, Kieffer Y, Mencattini A, et al. An Extracellular matrix-producing subset of cancer-associated fibroblasts drives chemoresistance in breast cancer via SRC activation and G0S2 upregulation. Cancer Res. 2025. Available from:\u00a0https:\/\/aacrjournals.org\/cancerres\/article\/doi\/10.1158\/0008-5472.CAN-25-0966\/767237\/An-Extracellular-Matrix-Producing-Subset-of-Cancer.\u00a0Cited 2026 Jan 13.","DOI":"10.1158\/0008-5472.CAN-25-0966"},{"key":"15680_CR26","doi-asserted-by":"publisher","first-page":"107111","DOI":"10.1016\/j.oraloncology.2024.107111","volume":"160","author":"G Marret","year":"2025","unstructured":"Marret G, Lamy C, Vacher S, et al. Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA. Oral Oncol. 2025;160:107111.","journal-title":"Oral Oncol"},{"key":"15680_CR27","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1016\/j.csbj.2025.08.035","volume":"27","author":"A Dubray-Vautrin","year":"2025","unstructured":"Dubray-Vautrin A, Gravrand V, Marret G, et al. Internal validation strategy for high dimensional prognosis model: a simulation study and application to transcriptomic in head and neck tumors. Comput Struct Biotechnol J. 2025;27:3792\u2013802.","journal-title":"Comput Struct Biotechnol J"},{"key":"15680_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12874-025-02709-9","volume":"25","author":"A Dubray-Vautrin","year":"2025","unstructured":"Dubray-Vautrin A, Choussy O, Lamy C, et al. A clustering-stratified cross-validation framework for validating omics survival models: application to head and neck cancer. BMC Med Res Methodol. 2025;25:277.","journal-title":"BMC Med Res Methodol"},{"key":"15680_CR29","doi-asserted-by":"crossref","unstructured":"Fossen EIF, Moreira-Soares M, LeBlanc M, et al. External validation of prognostic and predictive gene signatures in head and neck cancer patients. 2024. Available from:\u00a0http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.09.24.24314278.\u00a0Cited 2026 Jan 13.","DOI":"10.1101\/2024.09.24.24314278"},{"issue":"7","key":"15680_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1158\/1078-0432.CCR-24-2669","volume":"31","author":"M Michel","year":"2025","unstructured":"Michel M, Heidary M, Mechri A, et al. Noninvasive multicancer detection using DNA hypomethylation of LINE-1 retrotransposons. Clin Cancer Res. 2025;31(7):1275\u201391.","journal-title":"Clin Cancer Res"},{"key":"15680_CR31","doi-asserted-by":"crossref","unstructured":"Servant N, Rom\u00c3\u00a9jon J, Gestraud P, et al. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet 5. 2014. Available from:\u00a0http:\/\/journal.frontiersin.org\/article\/10.3389\/fgene.2014.00152\/abstract.\u00a0Cited 2023 Dec 6.","DOI":"10.3389\/fgene.2014.00152"},{"key":"15680_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2016.340","volume":"115","author":"S Samuels","year":"2016","unstructured":"Samuels S, Balint B, Von Der Leyen H, et al. Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study. Br J Cancer. 2016;115:1575\u201383.","journal-title":"Br J Cancer"},{"key":"15680_CR33","doi-asserted-by":"publisher","first-page":"100106","DOI":"10.1016\/j.esmoop.2021.100106","volume":"6","author":"E De Guillebon","year":"2021","unstructured":"De Guillebon E, Jimenez M, Mazzarella L, et al. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. ESMO Open. 2021;6:100106.","journal-title":"ESMO Open"},{"key":"15680_CR34","doi-asserted-by":"crossref","unstructured":"Patil S, Majumdar B, Awan KH et al. Cancer oriented biobanks: a comprehensive review. Oncol Rev. 2018. Available from:\u00a0https:\/\/www.frontierspartnerships.org\/articles\/10.4081\/oncol.2018.357.\u00a0Cited 2023 Dec 6.","DOI":"10.4081\/oncol.2018.357"},{"key":"15680_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","volume":"34","author":"NC Turner","year":"2023","unstructured":"Turner NC, Swift C, Jenkins B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2023;34:200\u201311.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15680-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:33:52Z","timestamp":1781631232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15680-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15680"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15680-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided signed informed consent. All methods and study procedures were conducted in accordance with the Declaration of Helsinki, applicable French regulations governing biomedical research involving human participants, and the GDPR.SCANDARE was approved by a national research ethics committee (CPP Ile-de-France 3) and the French National Agency for the Safety of Medicines and Health Products (ANSM) on December 09th, 2016.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Emanuela Romano: Bristol-Myers Squibb (BMS), AstraZeneca, Janssen-Cilag, Replimmune and Fonds Amgen France pour la Science et l\u2019Humain. Manuel Rodrigues: AstraZeneca, GlaxoSmithKline, Immunocore, MSD, Johnson & Johnson\/Janssen and Daiichi Sankyo\/UCB Japan. Jean-Yves Pierga: Novartis, Daiichi Sankyo, Astra Zeneca, Gilead Sciences, Roche\/Genentech, Pfizer, Roche\/Genentech, MSD Oncology, Lilly, Seagen, Eisai Europe, Exact Sciences, Veracyte, Menarini Group and Servier. Maud Kamal: Roche and AstraZeneca. Christophe Le Tourneau: Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology and Seattle Genetics. No other potential conflicts of interest were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}